CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.27
-0.03 (-0.57%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.30
Open5.07
Bid4.21 x 3000
Ask5.55 x 3100
Day's Range5.07 - 5.33
52 Week Range2.11 - 9.25
Volume285,328
Avg. Volume242,803
Market Cap221.426M
Beta (3Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateMar 6, 2020 - Mar 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.20
  • GlobeNewswire

    Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WALTHAM, Mass., Nov. 26, 2019 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • Thomson Reuters StreetEvents

    Edited Transcript of CHMA earnings conference call or presentation 5-Nov-19 10:00pm GMT

    Q3 2019 Chiasma Inc Earnings Call

  • GlobeNewswire

    Chiasma to Present at the 13th Acromegaly Consensus Conference

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that William Ludlam, M.D., Ph.D., Senior Vice President of Clinical Development and Medical Affairs, will present at the 13th Acromegaly Consensus Conference, to be held from November 17th-19th in Fort Lauderdale, Florida. Dr. Ludlam is scheduled to present on Sunday, November 17th. “We are pleased to be sharing positive top-line data from our Phase 3 CHIASMA OPTIMAL trial of MYCAPSSA®, that is being developed for the maintenance treatment of adult acromegaly patients, at the conference this year,” said Dr. William Ludlam.

  • Hedge Funds Have Never Been More Bullish On Chiasma Inc (CHMA)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Chiasma Inc (CHMA)

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • GlobeNewswire

    Chiasma Reports Third Quarter 2019 Results

    CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA® NDA on track for submission by year-end.

  • GlobeNewswire

    Chiasma Supports Acromegaly Awareness Day

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognizes November 1st as Acromegaly Awareness Day. “We recognize Acromegaly Awareness Day each year to call attention to this rare and debilitating disease, and to highlight the significant treatment burdens faced by patients and their families and the need for new maintenance treatment options,” said Raj Kannan, Chief Executive Officer of Chiasma. “Today, the Acromegaly Community is pleased to recognize Acromegaly Awareness Day, which reflects on our mission to provide an emotional and communal support network for people touched by acromegaly,” said Jill Sisco, President of the Acromegaly Community.

  • GlobeNewswire

    Chiasma to Report Third Quarter Financial Results on November 5, 2019

    WALTHAM, Mass., Oct. 29, 2019 -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • We're Not Very Worried About Chiasma's (NASDAQ:CHMA) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Chiasma's (NASDAQ:CHMA) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Chiasma to Present at the Cantor 2019 Global Healthcare Conference

    WALTHAM, Mass., Sept. 25, 2019 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • TheStreet.com

    3 Small Biotechs With Favorable Risk Vs. Reward Profiles

    BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.

  • What Makes Chiasma (CHMA) a New Buy Stock
    Zacks

    What Makes Chiasma (CHMA) a New Buy Stock

    Chiasma (CHMA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • What Kind Of Shareholder Owns Most Chiasma, Inc. (NASDAQ:CHMA) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Chiasma, Inc. (NASDAQ:CHMA) Stock?

    A look at the shareholders of Chiasma, Inc. (NASDAQ:CHMA) can tell us which group is most powerful. Institutions will...

  • GlobeNewswire

    Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a Key Opinion Leader (KOL) breakfast on maintenance therapy of adult patients with acromegaly on Thursday, September 12, 2019 in New York City. The meeting will feature a presentation by KOL Susan Samson, MD, PhD, from the Pituitary Center at Baylor St. Luke's Medical Center, and Jill Sisco, from the Acromegaly Community, who will discuss the current treatment landscape, as well as the unmet medical need for treating adults with acromegaly.

  • Thomson Reuters StreetEvents

    Edited Transcript of CHMA earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Chiasma Inc Earnings Call

  • Chiasma (CHMA) Upgraded to Buy: Here's Why
    Zacks

    Chiasma (CHMA) Upgraded to Buy: Here's Why

    Chiasma (CHMA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Chiasma Inc (CHMA) Q2 2019 Earnings Call Transcript
    Motley Fool

    Chiasma Inc (CHMA) Q2 2019 Earnings Call Transcript

    CHMA earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Chiasma Reports Second Quarter 2019 Results

    Announces positive data from Phase 3 CHIASMA OPTIMAL trial; MYCAPSSA® NDA submission expected by year-end 2019 with an expected six-month PDUFA review time period MPOWERED.

  • GlobeNewswire

    Chiasma to Report Second Quarter Financial Results on August 8, 2019

    WALTHAM, Mass., Aug. 01, 2019 -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • Steven Cohen Charges Into Chiasma
    GuruFocus.com

    Steven Cohen Charges Into Chiasma

    Guru invests in clinical-stage biopharmaceutical company Continue reading...

  • GlobeNewswire

    Chiasma Announces Pricing of Underwritten Public Offering of $55.0 Million of Common Stock

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $5.50 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Chiasma. In addition, Chiasma has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Piper Jaffray & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering.

  • GlobeNewswire

    Chiasma Announces Proposed Offering of Common Stock

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has commenced an underwritten public offering of its common stock. In addition, Chiasma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares to be sold in the offering are to be sold by Chiasma.

  • Benzinga

    Here Is What's Driving The Rally In Chiasma

    Thinly-traded micro-cap biotech Chiasma Inc (NASDAQ: CHMA ) is advancing strongly in reaction to a clinical trial readout from the company . What Happened Chiasma announced positive top-line data from ...

  • GlobeNewswire

    Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly

    SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who.

  • One Thing To Remember About The Chiasma, Inc. (NASDAQ:CHMA) Share Price
    Simply Wall St.

    One Thing To Remember About The Chiasma, Inc. (NASDAQ:CHMA) Share Price

    Anyone researching Chiasma, Inc. (NASDAQ:CHMA) might want to consider the historical volatility of the share price...

  • Benzinga

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...